Cardiovascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing

LAS VEGAS, April 21 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. has announced that the Over the Counter Bulletin Board (OTCBB), on which CVBT's stock is traded, has added a temporary "E" to the end of its ticker symbol. The temporary "E" designates the late filing of the Company's Annual Report (Form 10-K).

Pursuant to OTCBB rules, CVBT's listing will continue through May 15, 2008 provided the Company files it Annual Report before this date. After the OTCBB confirms the filing, the "E" will be removed from the ticker symbol.

On Friday, April 18th, CVBT submitted a Form 8-K stating that it was unable to file its Annual Report on time as additional time was necessary to ensure adequate disclosure of required information.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials underway in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. An additional trial is also being conducted in patients with chronic back pain who may have perfusion defects to their spine.

CardioVascular BioTherapeutics, Inc.

Allison Lipson, (702) 839-7200

alipson@cvbt.com

CONTACT: Allison Lipson of CardioVascular BioTherapeutics, Inc.,
+1-702-839-7200, alipson@cvbt.com

Web site: http://www.cvbt.com/